| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193692 | Annals of Allergy, Asthma & Immunology | 2006 | 7 Pages |
Abstract
This oral desensitization protocol appears to help some leukemic patients with recurrent rash tolerate imatinib mesylate, thus permitting continuation of this life-prolonging therapy. These findings suggest that some adverse cutaneous reactions to imatinib may be due to a hypersensitivity mechanism rather than a pharmacologic effect.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Robert P. MD, Kenneth MD, Kelly E. NP, Srinivasan MD, Chris PharmD, Larry D. MD,